[go: up one dir, main page]

MA27197A1 - Sels de tolterodine - Google Patents

Sels de tolterodine

Info

Publication number
MA27197A1
MA27197A1 MA27908A MA27908A MA27197A1 MA 27197 A1 MA27197 A1 MA 27197A1 MA 27908 A MA27908 A MA 27908A MA 27908 A MA27908 A MA 27908A MA 27197 A1 MA27197 A1 MA 27197A1
Authority
MA
Morocco
Prior art keywords
compounds
carbon atoms
tolterodine
acid
salts
Prior art date
Application number
MA27908A
Other languages
English (en)
Inventor
Michael Hawley
Walter Morozowich
Satish Kumar Singh
Mark P Warchol
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of MA27197A1 publication Critical patent/MA27197A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

DEPOSANT Société dite : PHARMACIA & UPJOHN COMPANY LLC REVENDICATION DE PRIORITES US 23 Avril 2002 10/127,875 Voir en annexe le titre de l'invention et le texte de l'abrégé Sels de toltérodine La présente invention concerne des composés pharmaceutiquement actifs nouveaux, des compositions pharmaceutiques contenant ces composés, l'utilisation de ces composés comme médicaments, et l„utilisation des composés pour la production de médicaments spécifiques. La présente invention concerne également une méthode de traitement comprenant l'administration des composés. Plus précisément, les composés sont des sels pharmaceutiquement acceptables de toltérodine ou d'hydroxytoltérodine, le sel étant le sel d'un acide choisi dans le groupe consistant en des acides aliphatiques mono- et dicarboxyliques comprenant 7 à 24 atomes de carbone, des acides alcanedisulfoniques comprenant 2 à 4 atomes de carbone, des dérivés d'acide naphtoïque comprenant 11 à 27 atomes de carbone, l'acide maléique et l'acide fumarique.
MA27908A 2002-04-23 2004-10-14 Sels de tolterodine MA27197A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/127,875 US7005449B2 (en) 2002-04-23 2002-04-23 Tolterodine salts

Publications (1)

Publication Number Publication Date
MA27197A1 true MA27197A1 (fr) 2005-01-03

Family

ID=29215346

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27908A MA27197A1 (fr) 2002-04-23 2004-10-14 Sels de tolterodine

Country Status (25)

Country Link
US (1) US7005449B2 (fr)
EP (1) EP1496882B1 (fr)
JP (1) JP2005535578A (fr)
KR (1) KR20040104585A (fr)
CN (1) CN1646110A (fr)
AP (1) AP2004003160A0 (fr)
AT (1) ATE334665T1 (fr)
AU (1) AU2003237724A1 (fr)
BR (1) BR0309439A (fr)
CA (1) CA2483092A1 (fr)
DE (1) DE60307258T2 (fr)
EA (1) EA200401108A1 (fr)
EC (1) ECSP045373A (fr)
ES (1) ES2266828T3 (fr)
HR (1) HRP20040990A2 (fr)
IL (1) IL164109A0 (fr)
IS (1) IS7462A (fr)
MA (1) MA27197A1 (fr)
MX (1) MXPA04010472A (fr)
NO (1) NO20044449L (fr)
OA (1) OA12810A (fr)
PL (1) PL371743A1 (fr)
TN (1) TNSN04212A1 (fr)
TW (1) TW200306802A (fr)
WO (1) WO2003090734A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496806A1 (fr) * 2002-08-28 2004-03-11 Pharmacia Corporation Composition liquide de tolterodine administree par voie orale
US7393874B2 (en) * 2003-04-08 2008-07-01 Hetero Drugs Limited Polymorphs of tolterodine tartrate
EP1620083A2 (fr) * 2003-04-18 2006-02-01 Pharmacia & Upjohn Company LLC Polytherapies
EP1701932B1 (fr) * 2003-12-24 2012-07-18 Cipla Ltd. Tolterodine, compositions et leurs utilisations, et preparations desdites compositions
EP1629834A1 (fr) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Composition pharmaceutique de tolterodine avec liberation soutenue
ITMI20060110A1 (it) * 2006-01-24 2007-07-25 Dipharma Spa Procedimento per la purificazione di tolterodina
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
WO2009019599A2 (fr) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Compositions à libération prolongée comprenant de la toltérodine
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
ITMI20082055A1 (it) * 2008-11-19 2009-02-18 Dipharma Francis Srl Procedimento per la preparazione di (r)-tolterodina base libera
EP2416761B1 (fr) * 2009-05-11 2015-02-11 ratiopharm GmbH Desfésotérodine sous forme d'un sel d'acide tartrique
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
IT1403094B1 (it) 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
GB201402556D0 (en) * 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
CN111728957B (zh) * 2020-07-06 2022-04-19 济南大学 一种托特罗定长效缓释微球及其制备方法
CN111925294A (zh) * 2020-07-06 2020-11-13 济南大学 一种托特罗定帕莫酸盐及其制备方法
CN115814090B (zh) * 2022-11-22 2024-05-24 广州医科大学附属第一医院 烟草引发炎症的药物靶点
US12150922B1 (en) * 2023-12-08 2024-11-26 King Faisal University Methods of inhibiting cyclooxygenase (COX) using tolterodine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
KR20000057548A (ko) * 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma

Also Published As

Publication number Publication date
ECSP045373A (es) 2004-11-26
DE60307258T2 (de) 2007-10-25
EA200401108A1 (ru) 2005-06-30
NO20044449L (no) 2004-10-26
KR20040104585A (ko) 2004-12-10
ES2266828T3 (es) 2007-03-01
EP1496882A1 (fr) 2005-01-19
US7005449B2 (en) 2006-02-28
HRP20040990A2 (en) 2004-12-31
TW200306802A (en) 2003-12-01
CA2483092A1 (fr) 2003-11-06
WO2003090734A1 (fr) 2003-11-06
ATE334665T1 (de) 2006-08-15
IS7462A (is) 2004-09-20
IL164109A0 (en) 2005-12-18
JP2005535578A (ja) 2005-11-24
EP1496882B1 (fr) 2006-08-02
TNSN04212A1 (fr) 2007-03-12
OA12810A (en) 2006-07-11
US20030199582A1 (en) 2003-10-23
AP2004003160A0 (en) 2004-12-31
BR0309439A (pt) 2005-02-15
CN1646110A (zh) 2005-07-27
AU2003237724A1 (en) 2003-11-10
MXPA04010472A (es) 2005-07-14
DE60307258D1 (de) 2006-09-14
PL371743A1 (en) 2005-06-27

Similar Documents

Publication Publication Date Title
MA27197A1 (fr) Sels de tolterodine
RU2203274C2 (ru) Спироциклические ингибиторы металлопротеаз
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA26952A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, utiles comme agents anti-inflammatoires et analgesiques.
MA27153A1 (fr) Formulations pharmaceutiques de derives de platine
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN04137A1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
CA2656716C (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
AU2736088A (en) Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
KR960037675A (ko) 벤조니트릴 및 벤조플루오라이드
DK0654041T3 (da) Peptidyl-4-amino-2,2-difluor-3-oxo-1,6-hexandisyre-derivater som anto-inflammatoriske midler
BE1002102A4 (fr) Derives de l'acide quinoleinecarboxylique.
KR960017663A (ko) 결합 수용체 길항물질
CA2143252A1 (fr) Derives de benzodioxane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR890005036A (ko) 아미드화합물, 이들의 제조방법 및 이들 화합물을 함유하여 위신경기능을 활성화하는 조성물
HU9800970D0 (en) Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
AU3623399A (en) Use of benzofuroxan derivatives in treating angina pectoris
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
ATE243202T1 (de) Neue antivirale, homocarbozklische nukleosidderivate von substituierten pyrimidindionen, verfahren zu ihrer herstellung und zusammensetzungen, die diese als aktiven bestandteil enthalten